Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863852 | 0.90 | ESR1 (0.57) | HTR7ESR1CNR2HPGDKMT2A | |
| SCHEMBL5863848 | 0.83 | CCR3 (0.53) | SIGMAR1ESR1OPRM1HTR2A | |
| SCHEMBL5863792 | 0.82 | ESR1 (0.53) | ESR1CNR2HPGDKMT2ACNR1 | |
| SCHEMBL5863752 | 0.80 | ESR1 (0.48) | ESR1CNR2HPGDKMT2ACNR1 | |
| SCHEMBL5864358 | 0.77 | ESR1 (0.49) | ESR1CNR2HPGDKMT2ACNR1 | |
| SCHEMBL5539548 | 0.76 | SIGMAR1 (0.79) | HTR7SIGMAR1OPRM1 | |
| SCHEMBL6295367 | 0.76 | ESR1 (0.88) | ESR1CNR2KMT2ACNR1LMNA | |
| SCHEMBL5863970 | 0.75 | ESR1 (0.54) | ESR1CNR2CNR1LMNA | |
| SCHEMBL5863831 | 0.75 | ESR1 (0.63) | SIGMAR1ESR1CNR2CNR1LMNA | |
| SCHEMBL5863359 | 0.74 | ESR1 (0.65) | ESR1CNR2CNR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | HTR7 2347/4885SIGMAR1 467/4885ESR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.